FrancophonIA/ELRC3.0 huggingface dataset:
English: If Efavirenz/Emtricitabine /Tenofovir disoproxil Krka is used with nephrotoxic medicinal products, renal function should be closely monitored according to the recommended schedule.
Danish: Hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bruges samtidig med nefrotoksiske lægemidler, skal nyrefunktionen nøje monitoreres i henhold til det anbefalede skema.
English: Co-administration of efavirenz/emtricitabine/tenofovir disoproxil with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir.
Danish: Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka med elbasvir/grazoprevir er kontraindiceret, da det kan medføre tab af det virologiske respons på elbasvir/grazoprevir.
English: Nervous system symptoms are common with efavirenz, one of the components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Danish: Symptomer fra nervesystemet er almindelige med efavirenz, et af de aktive stoffer i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: In a 144-week open-label randomised clinical study (GS-01-934) antiretroviral treatment-naïve HIV-1 infected patients received either a once-daily regimen of efavirenz, emtricitabine and tenofovir disoproxil or a fixed combination of lamivudine and zidovudine administered twice daily and efavirenz once daily (please refer to the Summary of Product Characteristics for emtricitabine/tenofovir disoproxil).
Danish: I et 144-ugers åbent, randomiseret, klinisk studie (GS-01-934), hvor antiretroviralt-behandlingsnaive hiv-1-inficerede patienter enten fik et regime en gang dagligt af efavirenz/emtricitabin/tenofovirdisoproxil eller en fast kombination af lamivudin og zidovudin, som blev givet to gange dagligt og efavirenz en gang dagligt (se produktresuméet for efavirenz/emtricitabin/tenofovirdisoproxil).
English: Some examples include: aminoglycosides, vancomycin (medicines for bacterial infections) foscarnet, ganciclovir, cidofovir (medicines for viral infections) amphotericin B, pentamidine (medicines for fungal infections) interleukin-2 (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
Danish: Aminoglykosider, vancomycin (mod bakterieinfektioner) Foscarnet, ganciclovir, cidofovir (mod virusinfektioner) Amphotericin B, pentamidin (mod svampeinfektioner) interleukin-2 (til behandling af kræft),
English: If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is stopped, speak to your doctor before you restart taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tablets.
Danish: Hvis du holder op med at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, skal du kontakte din læge, før du begynder at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka-tabletter igen.
English: Rare completed suicide delusion
Danish: Fuldbyrdet selvmord vrangforestillinger neuroser
English: If you throw up the tablet (within 1 hour after taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka), you should take another tablet.
Danish: Hvis du kaster op (inden for en time efter du har taget Efavirenz/Emtricitabine/Tenofovir disoproxil Krka), bør du tage en ny tablet.
English: It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of efavirenz/emtricitabine/tenofovir disoproxil on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section 5.1).
Danish: Det forudses, at tenofovir-eksponeringen (AUC) vil være ca. 30% lavere efter administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka på tom mave sammenlignet med tenofovirdisoproxil, når denne tages som individuel komponent sammen med mad (se pkt.
English: Use of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka in combination with saquinavir as the sole protease inhibitor is not recommended.
Danish: Anvendelse af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i kombination med saquinavir som den eneste protease-hæmmer frarådes.
English: No dose adjustment is recommended.
Danish: Der kræves ingen dosisjustering.
English: 3, dizziness (8.5%)
Danish: 3, svært udslæt (<1%)
English: Pregnancy should be avoided in women receiving Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Danish: Graviditet bør undgås hos kvinder, der får Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes, such as: antiarrhythmics of classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole), cisapride, flecainide, certain antimalarials and methadone (see section 4.3).
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er kontraindiceret ved samtidig brug af lægemidler, som vides at forlænge QTc-intervallet og kan føre til Torsade de Pointes, f.eks. antiarytmika af klasse IA og III, neuroleptika og antidepressiva, visse antibiotika, herunder nogle stoffer af følgende klasser: makrolider, fluorokinoloner, imidazol- og triazol-antimykotika, visse nonsederende antihistaminer (terfenadin, astemizol), cisaprid, flecainid, visse antimalariamidler og methadon (sepkt.
English: As Efavirenz/Emtricitabine/Tenofovir disoproxil Krka contains efavirenz, emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Danish: Da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka indeholder efavirenz, emtricitabin og tenofovirdisoproxil, kan interaktioner, som er identificeret med disse lægemidler individuelt, opstå med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Hepatic failure with efavirenz
Danish: Leversvigt med efavirenz
English: Interaction with didanosine Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Danish: Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og didanosin anbefales ikke, da det resulterer i en stigning i systemisk eksponering for didanosin på 40-60%, hvilket kan øge risikoen for didanosin-relaterede bivirkninger (se pkt.
English: General disorders and administration site conditions: Very common asthenia
Danish: Almene symptomer og reaktioner på administrationsstedet Meget almindelig
English: Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1).
Danish: Patienter må ikke tidligere have oplevet virologisk svigt under antiretroviral behandling, og de må ikke før deres første antiretrovirale behandling have haft virustammer med mutationer, der kan give signifikant resistens over for en eller flere af de tre komponenter, som Efavirenz/Emtricitabine/Tenofovir disoproxil Krka indeholder (se pkt.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may interact with other medicines, including herbal preparations such as Ginkgo biloba extracts.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan påvirke virkningen af anden medicin, herunder naturlægemidler med Ginkgo bilobaekstrakt (tempeltræekstrakt).
English: Dose adjustment: If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is co-administered with rifampicin to patients weighing 50 kg or more, an additional 200 mg/day (800 mg total) of efavirenz may be considered (see section 4.5).
Danish: Dosisjustering: Hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka gives samtidigt med rifampicin til patienter, der vejer 50 kg eller derover, kan det overvejes at give yderligere 200 mg efavirenz/dag (800 mg i alt) (se pkt.
English: For co-administration of efavirenz with lowdose ritonavir in combination with a protease inhibitor, see section on ritonavir below.
Danish: Mht. samtidig administration af efavirenz og lavdosis ritonavir i kombination med en protease-hæmmer se afsnittet om ritonavir nedenfor.
English: The recommended dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is one tablet taken orally once daily.
Danish: Den anbefalede dosis af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er én tablet, taget oralt, én gang dagligt.
English: Nervous system disorders: Very common headache dizziness
Danish: Nervesystemet: Meget almindelig
English: Your doctor may need to consider giving you a different antifungal.
Danish: Din læge kan finde det nødvendigt at overveje at give dig et andet svampemiddel.
English: Your doctor may give you a different anticonvulsant.
Danish: Lægen kan give dig et andet krampestillende lægemiddel.
English: They usually begin during the first one or two days of efavirenz therapy and generally resolve after the first two to four weeks.
Danish: De debuterer sædvanligvis i løbet af de første 1-2 behandlingsdage med efavirenz og forsvinder som regel efter de første 2-4 uger.
English: These are listed under Do not take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, at the start of section 2.
Danish: Disse lægemidler er nævnt under Tag ikke Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i begyndelsen af punkt 2.
English: AUC: ↑ 21% (↑ 10 to ↑ 34) Cmax: ↑ 14% (↑ 4 to ↑ 26) Cmin: ↑ 25% (↑ 7 to ↑ 46) (inhibition of CYP-mediated oxidative metabolism)
Danish: AUC: ↑ 21% (↑ 10 til ↑ 34) Cmax: ↑ 14% (↑ 4 til ↑ 26) Cmin: ↑ 25% (↑ 7 til ↑ 46) (hæmning af CYP-medieret oxidativ metabolisme)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tablets should be swallowed whole with water, once daily.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tabletter skal synkes hele sammen med vand, én gang dagligt.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended if you have moderate to severe kidney disease.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør ikke anvendes, hvis du har moderat til alvorlig nyresygdom.
English: Increased transaminases
Danish: Forhøjet kreatininkinase
English: Lumefantrine: AUC: ↓ 21% Cmax: ↔
Danish: Lumefantrin: AUC: ↓ 21% Cmax: ↔
English: As a fixed combination, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other medicinal products containing the same active components, emtricitabine or tenofovir disoproxil.
Danish: Som en fast kombination bør Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ikke gives samtidigt med andre lægemidler, der indeholder de samme aktive komponenter, emtricitabin eller tenofovirdisoproxil.
English: Artemether/Lumefantrine/Emtricita bine
Danish: Artemether/lumefantrin/emtricitabi
English: Cmax: ↑ 11% (↑ 3 to ↑ 19) (CYP3A4 induction)
Danish: Cmax: ↑ 11% (↑ 3 til ↑ 19) (CYP3A4-induktion)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of itraconazole or posaconazole in your blood.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan nedsætte mængden af itraconazol eller af posaconazol i blodet.
English: It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
Danish: Desuden skal nyrefunktionen (kreatininclearance og serumphosphat) monitoreres efter to til fire ugers behandling, efter tre måneders behandling og derefter hver tredje til sjette måned hos patienter uden renale risikofaktorer.
English: Tests may also show: decreases in phosphate levels in the blood increased levels of creatine kinase in the blood that may result in muscle pain and weakness
Danish: Øget indhold af kreatinkinase i blodet som kan medføre muskelsmerter og -svaghed
English: Rarely, pancreatitis and lactic acidosis, sometimes fatal have been reported.
Danish: Der er rapporteret sjældne tilfælde af pancreatitis og laktatcidose, og nogle af disse tilfælde var fatale.
English: AUC: ↓ 13% Cmin: ↓ 31% Cmax: ↓ 15% (CYP3A4 induction)
Danish: AUC: ↓ 13% Cmin: ↓ 31% Cmax: ↓ 15% (CYP3A4-induktion)
English: Since Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed dose combination product, the dose of efavirenz cannot be altered (see section 4.5).
Danish: Da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er et fastdosis kombinationsprodukt, kan efavirenzdosis ikke ændres (se pkt.
English: No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.
Danish: Der er ingen tilgængelige data til at understøtte kombinationen af efavirenz/emtricitabine/tenofovirdisoproxil og andre antiretrovirale lægemidler.
English: Elderly patients are more likely to have decreased hepatic or renal function, therefore caution should be exercised when treating elderly patients with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (see section 4.2).
Danish: Da det er mere sandsynligt, at ældre patienter har nedsat lever- eller nyrefunktion, skal der udvises forsigtighed ved behandling af ældre patienter med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (se pkt.
English: Voriconazole/Tenofovir disoproxil Interaction not studied.
Danish: Voriconazole/ tenofovirdisoproxil Interaktion er ikke undersøgt.
English: No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve patients or in heavily pretreated patients.
Danish: Der er p.t. ingen tilgængelige data fra kliniske studier med efavirenz/emtricitabin/tenofovirdisoproxil til behandlingsnaive patienter eller til patienter, der tidligere har været i massiv behandling.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may cause dizziness, impaired concentration and drowsiness.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan give svimmelhed, nedsat koncentrationsevne og døsighed.
English: Ethinyloestradiol+Norgestimate/Ef avirenz (0.035 mg+0.25 mg q.d./600 mg q.d.)
Danish: Ethinylestradiol+norgestimat/efavir enz (0,035 mg+0,25 mg q.d./600 mg q.d.)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should be administered with caution to elderly patients (see section 4.4).
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør administreres med forsigtighed til ældre patienter (se pkt.
English: Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) Tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI)
Danish: Efavirenz er en ikke-nukleosid-revers transkriptase-hæmmer (NNRTI).
English: Effects on drug levels Mean percent change in AUC, Cmax, Cmin with 90% confidence intervals if available (mechanism)
Danish: Virkning på medicinniveauer Gennemsnitlig ændring (%) i AUC, Cmax,
English: When your supply of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka starts to run low, get more from your doctor or pharmacist.
Danish: Når din Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er ved at slippe op, skal du hente mere hos din læge eller på apoteket.
English: Due to similarities with emtricitabine, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other cytidine analogues, such as lamivudine.
Danish: På grund af ligheder med emtricitabin bør Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ikke administreres samtidigt med andre cytidinanaloger, såsom lamivudin.
English: Ginkgo biloba extracts (herbal preparation).
Danish: Ginkgo bilobaekstrakt (tempeltræekstrakt, et naturlægemiddel).
English: Once you start taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, look out for:
Danish: Når du begynder at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, skal du holde øje med:
English: It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er indiceret til behandling af human immundefekt virus-1 (hiv-1) infektion hos voksne i alderen 18 år og derover med virologisk suppression til hiv-1 RNA-koncentrationer <50 kopier/ml, som er i antiretroviral kombinationsbehandling og har været det i mere end 3 måneder.
English: Each film-coated tablet contains 600 mg of efavirenz (efavirenzum), 200 mg of emtricitabine (emtricitabinum) and 245 mg of tenofovir disoproxil (tenofovirum disoproxilum) (as succinate).
Danish: Hver filmovertrukken tablet indeholder 600 mg efavirenz (efavirenzum), 200 mg emtricitabin (emtricitabinum) og 245 mg tenofovirdisoproxil (tenofovirum disoproxilum) (som succinat).
English: N-monodesmethyl diltiazem: AUC: ↓ 37% (↓ 17 to ↓ 52) Cmax: ↓ 28% (↓ 7 to ↓ 44) Cmin: ↓ 37% (↓ 17 to ↓ 52)
Danish: N-monodesmethyldiltiazem: AUC: ↓ 37% (↓ 17 til ↓ 52) Cmax: ↓ 28% (↓ 7 til ↓ 44) Cmin: ↓ 37% (↓ 17 til ↓ 52)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with adefovir dipivoxil or with medicinal products containing tenofovir alafenamide.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka må ikke administreres samtidigt med adefovirdipivoxil eller med lægemidler, som indeholder tenofoviralafenamid.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may affect your kidneys.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan påvirke dine nyrer.
English: Concomitant administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is expected to decrease plasma concentrations of velpatasvir and voxilaprevir.
Danish: Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/ voxilaprevir forventes at reducere plasmakoncentrationen af velpatasvir og voxilaprevir.
English: You must remain under the care of your doctor while taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Danish: Du skal fortsat være i behandling hos din læge, mens du tager Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: These drugs include: antiarrhythmics of classes IA and III, neuroleptics, antidepressive agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole and triazole antifungal agents, certain non-sedating antihistamines (terfenadine, astemizole), cisapride, flecainide, certain antimalarials, methadone (see sections 4.4, 4.5 and 5.1).
Danish: Disse lægemidler omfatter: - antiarytmika af klasse IA og III - neuroleptika, antidepressiva - visse antibiotika, herunder stoffer fra følgende klasser: makrolider, fluorokinoloner, imidazol og triazol-antimykotika - visse non-sederende antihistaminer (terfenadin, astemizol) - cisaprid - flecainid - visse antimalariamidler
English: AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction)
Danish: AUC: ↑ 11% (↑ 5 til ↑ 18) Cmax: ↑ 16% (↑ 6 til ↑ 26) Cmin: ↑ 13% (↑ 1 til ↑ 26) (CYP3A4-induktion)
English: If the patient vomits within 1 hour of taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, another tablet should be taken.
Danish: Hvis patienten kaster op inden for 1 time efter at have taget Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, skal der tages en ny tablet.
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be avoided unless the benefit to the patient outweighs the risk.
Danish: Samtidig brug af posaconazol og Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør undgås, med mindre fordelene for patienten overstiger risici.
English: If you could get pregnant while receiving Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, you need to use a reliable form of barrier contraception (for example, a condom) with other methods of contraception including oral (pill) or other hormonal contraceptives (for example, implants, injection).
Danish: Hvis du kan blive gravid, er det nødvendigt, at du bruger en pålidelig form for barriereprævention (f.eks. kondom) sammen med andre former for prævention, herunder P-piller eller andre hormonale præventionsmidler (f.eks. implantat, injektion), mens du tager Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: If the patient vomits more than 1 hour after taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka he/she does not need to take another dose.
Danish: Hvis patienten kaster op mere end 1 time efter at have taget Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, skal patienten ikke tage en ny dosis.
English: You must not take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with certain medicines.
Danish: Du må ikke tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka sammen med visse andre lægemidler.
English: Treatment-emergent adverse reactions considered possibly or probably related to efavirenz/emtricitabine/tenofovir disoproxil reported in study AI266073 (over 48 weeks; n = 203), which have not been associated with one of the individual components of efavirenz/emtricitabine/tenofovir disoproxil, include:
Danish: Bivirkninger som er forbundet med anvendelse af efavirenz/emtricitabin/tenofovirdisoproxil: Bivirkninger [rapporteret i studie AI266073 (over 48 uger, n=203)], som opstod under behandlingen, og som blev anset for muligvis eller sandsynligvis at være relateret til efavirenz/emtricitabin/tenofovirdisoproxil, og som ikke er blevet relateret til et af de aktive stoffer i efavirenz/emtricitabin/tenofovirdisoproxil, omfatter:
English: Therefore Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be used during breast-feeding.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør derfor ikke anvendes under amning.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil.
Danish: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er en fastdosis-kombination af efavirenz, emtricitabin og tenofovirdisoproxil.
English: Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended since plasma concentrations of velpatasvir and voxilaprevir are expected to decrease following co-administration with efavirenz leading to reduced therapeutic effect of sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir (see section
Danish: Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/voxilaprevir frarådes, da plasmakoncentrationen af velpatasvir og voxilaprevir forventes at blive reduceret efter samtidig administration af efavirenz, som kan resultere i manglende terapeutisk virkning af sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/voxilaprevir (se pkt.
English: AUC: ↓ 60% (↓ 52 to ↓ 68) Cmax: ↓ 62% (↓ 55 to ↓ 78) (CYP3A4 induction)
Danish: AUC: ↓ 60% (↓ 52 til ↓ 68) Cmax: ↓ 62% (↓ 55 til ↓ 78) (CYP3A4-induktion)
English: Co-administration of ritonavir at doses of 600 mg and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is not recommended.
Danish: Samtidig administration af ritonavir i doser på 600 mg og Efavirenz/Emtricitabine/Tenofovir disoproxil Krka frarådes.
English: Morning Cmax: ↑ 24% (↑ 12 to ↑ 38) Evening Cmax: ↔
Danish: Cmax morgen: ↑ 24% (↑ 12 til ↑ 38) Cmax aften: ↔
English: Artemether/Lumefantrine/Tenofovi r disoproxil
Danish: Artemether/lumefantrin/ tenofovirdisoproxil